Method of predicting risk of lung cancer recurrence, and a composition, kit and microarray for the same

Abstract

Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.

1 . A method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method comprising:
 obtaining a biological sample from a lung cancer patient;   measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and   determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.   
     
     
         2 . The method of  claim 1 , wherein the obtaining of a biological sample is performed by obtaining lung cancer tissue. 
     
     
         3 . The method of  claim 1 , wherein the measuring of an expression level of a marker gene is performed by measuring an expression level of at least one marker gene selected from the group consisting of marker genes of Table 1. 
     
     
         4 . The method of  claim 1 , wherein the lung cancer is adenocarcinoma and the measuring of an expression level of a marker gene is performed by measuring an expression level of at least one marker gene selected from the group consisting of marker genes of Table 2. 
     
     
         5 . The method of  claim 1 , wherein the lung cancer is a squamous cell carcinoma and the measuring of an expression level of a marker gene is performed by measuring an expression level of at least one marker gene selected from the group consisting of marker genes of Table 3. 
     
     
         6 . The method of  claim 1 , wherein the measuring of an expression level of a marker gene is performed by measuring a level of mRNA or protein derived from the maker gene. 
     
     
         7 . The method of  claim 1 , wherein the determining of whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group is performed using a statistical forecasting model. 
     
     
         8 . The method of  claim 7 , wherein the statistical forecasting model is selected from the group consisting of an Linear Discrimination Analysis (LDA) model, Quadratic Discriminantion Analysis (QDA) prediction model, a Neural Network model, a Decision Tree model, a Support Vector Machine model and a Naive Bayes model. 
     
     
         9 . The method of  claim 1 , wherein the determining of whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group comprises determining the marker gene to correspond to a non-recurrence group if the expression level of the marker gene shows a statistically meaningful difference from the expression level of the recurrence group, or determining the marker gene to correspond to a recurrence group if the expression level of the marker gene shows a statistically meaningful difference from the expression level of the non-recurrence group. 
     
     
         10 . The method of  claim 9 , wherein the statistically meaningful difference is expressed as a p value that indicates a statistical meaning regarding the expression level of the recurrence group or the non-recurrence group. 
     
     
         11 . The method of  claim 10 , wherein the p value is less than 0.05. 
     
     
         12 . The method of  claim 1 , wherein the expression level is measured on a microarray. 
     
     
         13 . The method of  claim 12 , wherein the microarray is a nucleic acid microarray. 
     
     
         14 . The method of  claim 1 , wherein the expression level of the marker gene is determined by measuring the amount of an amplification product obtained by nucleic acid amplification that is carried out by a reverse transcriptase-polymerase chain reaction (RT-PCR) using RNA isolated from the biological sample as a template. 
     
     
         15 . The method of  claim 1 , wherein the expression level is measured by detecting protein coded by the marker gene. 
     
     
         16 . The method of  claim 15 , wherein the detecting of protein is performed by using an antibody specific to the protein. 
     
     
         17 . A method of preparing a report on the risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method comprising preparing a report representing predicted results according to  claim 1 . 
     
     
         18 . The method of  claim 17 , wherein the report comprises probability of recurrence according to time. 
     
     
         19 . A report on a risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, which is prepared by the method according to  claim 17 . 
     
     
         20 . A composition for diagnosing the risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, comprising at least one probe or probe set selected from marker genes selected from the group consisting of marker genes of Tables 1, 2 and 3. 
     
     
         21 . A kit for diagnosing the risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the kit comprising at least one probe or probe set selected from marker genes selected from the group consisting of marker genes of Tables 1, 2 and 3. 
     
     
         22 . The kit of  claim 21 , wherein the probe or probe set is immobilized on a microarray. 
     
     
         23 . A kit for diagnosing the risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, comprising a sense and anti-sense primer pair for each of at least one marker gene selected from the group consisting of marker genes of Tables 1, 2 and 3. 
     
     
         24 . A microarray for diagnosing a risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, in which at least one probe or probe set selected from marker genes selected from the group consisting of marker genes of Tables 1, 2 and 3 is immobilized on a substrate.